Evidence map›Paper›PMID 32603496›Full record

SynthesisTransplant infectious disease : an official journal of the Transplantation Society2020

Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.

Colin Anderson-Smits, Erin R Baker, Ishan Hirji

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Transplant infectious disease : an official journal of the Transplantation Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Is CMV PCR Monitoring Necessary in Patients with Hematological Malignancy Receiving Chemotherapy? A Prospective Single-Center StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Torque Teno Virus: A Promising Biomarker in Kidney Transplant Recipients.International journal of molecular sciences · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Colin Anderson-SmitsShire, A Takeda Company, Cambridge, MA, USA.ORCID https://orcid.org/0000-0002-2734-6154
Erin R BakerCTI Clinical Trial & Consulting Services, Covington, KY, USA.
Ishan HirjiShire, A Takeda Company, Cambridge, MA, USA.
Takeda (United States) · USClinical Trial and Consulting · US

Funding

Shire International GmbH
6 · The paper itself

Abstract

backgroundIn transplant recipients, cytomegalovirus (CMV) infection increases morbidity and mortality; furthermore, coinfection with other human herpesviruses like the Epstein-Barr virus (EBV) may complicate their management. This systematic literature review aimed to summarize rates of CMV-EBV coinfection and associated clinical outcomes among solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.

methodsAn electronic literature search was performed using pre-specified search strategies (January 1, 2010-October 31, 2018) and following established/best practice methodology. Of 316 publications identified, 294 did not report CMV-EBV coinfection and were excluded. Studies meeting the inclusion criteria were further analyzed. Due to limited reporting/heterogeneity, data were not meta-analyzable.

resultsNine studies (six SOT; three HSCT) reported CMV-EBV coinfection; rates of coinfection post transplantation varied between 2.6% and 32.7%. Two studies indicated CMV reactivation to be an independent variable associated with EBV reactivation. Among SOT studies, higher rates of graft dysfunction (47.4% vs 22.9%), rejection episodes (20.0% vs 8.9%), or acute rejection (50.0% vs 31.0%) were reported for patients with coinfection than without. In HSCT studies, patients with graft-vs-host disease were not reported separately for coinfection. Two studies described cases of post-transplant lymphoproliferative disorder (PTLD) in patients with CMV-EBV coinfection and reported rates of PTLD of 92% and 100%.

conclusionThe CMV-EBV coinfection rate in HSCT and SOT recipients varied and was associated with increased graft rejection and PTLD compared with patients without coinfection. Further research may improve understanding of the burden of CMV-EBV coinfection among transplant recipients.

Indexed as

CoinfectionCytomegalovirus InfectionsEpstein-Barr Virus InfectionsLymphoproliferative DisordersTransplant RecipientsCytomegalovirusHerpesvirus 4, HumanHumanscytomegalovirusEpstein-Barr virushematopoietic stem cell transplantsolid organ transplant

Identifiers

PMID32603496
PMCPMC7816247
OpenAlexW3038508904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.